Form 4: Elanco Executive Ramiro Martin Cabral Reports Stock Transactions

Elanco Animal Health's Executive Vice President, Ramiro Martin Cabral, reports acquisition of restricted stock units and stock options, along with disposition of shares to cover tax liabilities.

Summary

• On March 1, 2024, Ramiro Martin Cabral, an Executive Vice President at Elanco Animal Health, acquired 28,307 shares of common stock through a grant of restricted stock units.
• These restricted stock units vest in three equal installments on March 1, 2025, March 1, 2026, and March 1, 2027.
• On the same day, Cabral also disposed of 8,909 shares of common stock at a price of $16.03 to cover tax liabilities associated with the vesting of previously awarded restricted stock units.
• Additionally, Cabral was granted 61,735 stock options with an exercise price of $16.03, vesting in three equal installments on March 1, 2025, March 1, 2026, and March 1, 2027.
• Following these transactions, Cabral directly owns 169,048 shares of Elanco common stock and 61,735 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transactions are routine and reflect standard executive compensation practices. The grants suggest confidence in the company's future performance.

Positives

• The grant of restricted stock units and stock options to a key executive aligns their interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the stock options and restricted stock units suggests an expectation of continued growth and value creation over the next three years.

Industry Context

Executive compensation packages including stock options and restricted stock units are common in the animal health industry to incentivize performance and retain key talent. These grants align executive interests with shareholder value.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard practice for executive compensation in publicly traded animal health companies.
• Companies like Zoetis and IDEXX Laboratories also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules (one-third annually over three years) are typical for these types of grants.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they involve the issuance of new shares and the disposition of existing shares by an executive.
• The grants incentivize the executive to work towards increasing shareholder value.

Key Dates